Skip to main content
SpringerLink
Log in

Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Nine patients with recurrent glioblastoma were given autologous adherent lymphokine-activated killer (A-LAK) cells and interleukin-2 (IL-2) administered directly into the tumor cavity through an Ommaya tube placed during surgery/biopsy. The immunotherapy was well tolerated and the response rate was 33% (one complete response, two partial responses, four with stable disease and two with progressive disease). However, survival 18 months from initial diagnosis did not differ from that reported in the literature for patients treated conventionally. Serial determinations of IL-2 in the tumor cavity during the course of treatment revealed that IL-2 concentrations were sufficient to maintain lymphocyte activation. Since steroid medication was discontinued during treatment and A-LAK cells have greater antitumor activity than standard LAK cells, other factors are discussed that might explain the limited results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Burger PC, Boyko OB (1991) The pathology of the central nervous system radiation injury. In: Gutin PH, Leibel SA, Sheline GE (eds) Radiation injury to the nervous system. Raven Press, New York, p 236

    Google Scholar 

  2. Chocair AK, Levin VA, Gutin PH, Davis RL, Silver P, Edwards MSB, Wilson CB (1986) Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65: 654

    PubMed  Google Scholar 

  3. Denicoff KD, Rubinov DR, Papa MZ, Simpson C, Seipp CA, Lotze MT, Chang AE, Rosestein D, Rosenberg SA (1987) The neuropsychiatric effects of the treatment with interleukin-2 and lymphokine-activated killer cells. Ann Int Med 107: 293

    PubMed  Google Scholar 

  4. Gillis S, Ferm MM, Ou W, Smith KA (1978) T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol 120: 2027

    PubMed  Google Scholar 

  5. Gutin PH, Leibel SA, Wara WM, Chouchair A, Levin VA, Philips TL, Silver P, Da Silva V, Edwards MSB, Davis RL, Weaver KA, Lamb S (1987) Recurrent malignant gliomas: Survival following interstitial brachitherapy with high-activity iodine-124 sources. J Neurosurg 67: 864

    PubMed  Google Scholar 

  6. Inge TH, Hoover SK, Susskind BM, Barret SK, Bear HD (1992) Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor-b1. Cancer Res 52: 1386

    PubMed  Google Scholar 

  7. Jaaskelainen J, Kalliomaki P, Paetau A, Timoen T (1989) Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multicellular human glioma spheroids as targets. J Immunol 142: 1036

    PubMed  Google Scholar 

  8. Jaaskelainen J, Maenpaa A, Patarroyo M, Gambher CG, Somersalo K, Tarkannen J, Kallio M, Timonen T (1992) Migration of recombinant IL-2 activated T and natural killer cells in the intracellular space of human H-2 glioma spheroid in vitro. A study on adhesion molecules involved. J. Immunol 149: 260

    PubMed  Google Scholar 

  9. Jacobs SK, Wilson DJ, Kornblith PL, Grimm EA (1986) Interleukin-2 or autologous lymphokine activated killer cell treatment of malignant glioma: phase I trial. Cancer Res 46: 2101

    PubMed  Google Scholar 

  10. Jaeckle KA, Mittelman A, Hill FH (1990) Phase II trial ofSerratia marcescens extract in recurrent malignant astrocytoma. J Clin Oncol 8: 1408

    PubMed  Google Scholar 

  11. Kelly KA, Kirkwood JM, Kapps DS (1984) Glioblastoma multiforme: pathology, natural history and treatment. Cancer Treat Rev 11: 1

    Google Scholar 

  12. Krueger JM, Walter C, Dinnarello CA, Wolff SM, Chedid L (1984) Sleep promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol 245: R 994

    Google Scholar 

  13. Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, De Tribolet N (1989) Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor-β2. J Neurosurg 71: 211

    PubMed  Google Scholar 

  14. Kuppner MC, Sawamura Y, Hamou MF, De Tribolet N (1990) Influence of PGE2 and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2 activated lymphocytes. J Neurosurg 72: 619

    PubMed  Google Scholar 

  15. Mahaley MS (1991) Neuro-oncology index and review (adult primary brain tumors. J Neurooncol 11: 85

    PubMed  Google Scholar 

  16. Mahaley MS, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S (1977) Immunobiology of primary intracranial tumors. Part I. Studies of the cellular and humoral general immune competence of brain tumor patients. J Neurosurg 46: 467

    PubMed  Google Scholar 

  17. Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB (1988) A new approach to generating antitumor effectors for adoptive immunotherapy using adherent lymphokine-activated killer cells. Cancer Res 48: 3461

    PubMed  Google Scholar 

  18. Merchant RE, Ellison MD, Young HF (1990) Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of preclinical and clinical investigation. J Neuroncol 8: 173

    Google Scholar 

  19. Merchant RE, Mc Vicar DW, Merchant LH, Young HF (1992) Treatment of recurrent malignant glioma by repeated intracerebral injection of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a phase I clinical trial. J Neurooncol 12: 75

    PubMed  Google Scholar 

  20. Mulé JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA (1988) Transforming growth factor-b inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95

    PubMed  Google Scholar 

  21. Nitta T, Sato K, Yagito H, Okumura K, Ishii S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368

    PubMed  Google Scholar 

  22. Palma L, Di Lorenzo N, Guidetti B (1978) Lymphocyte infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate and relevance to prognosis in 228 operated cases. J Neurosurg 49: 854

    PubMed  Google Scholar 

  23. Ruffini PA, Rivoltini L, Silvani A, Boiardi A, Parmiani G (1993) Factors, including transforming growth factor b, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 36: 409

    PubMed  Google Scholar 

  24. Schwharz RE, Vujanovic NL, Hiserodt JC (1989) Enhanced antimetastatic activity of lymphokine activated killer cells purified and expanded by their adherence to plastic. Cancer Res 49: 1441

    PubMed  Google Scholar 

  25. Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochoa AC (1991) Regulation of lymphokine activated killer activity and poreforming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor β. J Immunol 146: 3289

    PubMed  Google Scholar 

  26. Yoshida S, Tanaka R, Takai N, Ono K (1988) Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors. Cancer Res 48: 5011

    PubMed  Google Scholar 

  27. Whiteside TL, Wang YL, Selker RG, Herberman RB (1988) In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors. Cancer Res 48: 6069

    PubMed  Google Scholar 

  28. Tzeng JJ, Barth RF, Orosz CG, James SM (1991) Phenotype and functional activity of tumor-infiltrating lymphocytes isolated from immunogenic and non immunogenic rat brain tumors. Cancer Res 51: 2373

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto Nazionale Neurologico “C. Besta”, via Celoria 11, I-20133, Milan, Italy

    Amerigo Boiardi, Antonio Silvani, Giovanni Broggi & Andrea Salmaggi

  2. Istituto Nazionale dei Tumori, Milan, Italy

    Pier Adelchi Ruffini, Licia Rivoltini & Giorgio Parmiani

Authors
  1. Amerigo Boiardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Silvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pier Adelchi Ruffini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Licia Rivoltini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giorgio Parmiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giovanni Broggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Andrea Salmaggi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Boiardi, A., Silvani, A., Ruffini, P.A. et al. Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients. Cancer Immunol Immunother 39, 193–197 (1994). https://doi.org/10.1007/BF01533386

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01533386

Key words

Search

Navigation